1. Introduction {#s0005}
===============

During the last decade, nitrated lipid gained the interest of the scientific community, as new endogenous signaling molecules with important regulatory role in health and disease. Research on this is aimed at understanding the reactivity of reactive nitrogen species (RNS) with lipids, to unravel their occurrence in vivo and their biological roles. Among nitrated and nitroxidized lipids identified so far, the nitro-fatty acids (NO~2~-FA) are best-known products of RNS. These products have been widely detected in several tissues [@bib1], [@bib2], [@bib3], [@bib4], [@bib5] and biofluids [@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], and are nowadays a hot topic in nitro lipidomics. NO~2~-FA are considered important bioactive molecules and have been associated with anti-inflammatory [@bib6], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23], [@bib24], anti-hypertensive [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31], [@bib32], and anti-thrombotic properties [@bib31], [@bib33] and cytoprotective effects [@bib2], [@bib34], [@bib35], [@bib36], [@bib37]. More recently, other nitrated and nitroxidized lipids [@bib1], [@bib6], [@bib7], [@bib8], [@bib13], [@bib38] and also nitro derivatives of phospholipids (PL) [@bib39], [@bib40] and triglycerides (TAG) [@bib41] have been detected in biological samples and were associated with protective and beneficial effects, but they are scarcely studied. Also, esterified forms of NO~2~-FA have been found as they can be generated either by direct nitration of the esterified fatty acyl moiety or by the incorporation of NO~2~-FA [@bib41].

NO~2~-FA are also known as nitroalkenes derivatives of fatty acids since it includes a nitro group linked to the double bond (alkene group) of the unsaturated fatty acyl chain, and the nitro-alkene moiety makes these derivatives highly reactive with electrophilic properties. These endogenous electrophilic lipids are capable to covalently link to proteins, via Michael addition [@bib42], leading to the formation of lipoxidation adducts. This type of post-translational modification (PTM) of proteins can modulate protein function, which underlies some of the biological roles attributed to the NO~2~-FA ([Fig. 1](#f0005){ref-type="fig"}). Some of these PTMs are shown to elicit a protective effect, which may provide clues for new therapeutic strategies and new drugs.Fig. 1Schematic representation of nitrated lipids pathways: from their generation to their biological effect.Fig. 1

Detection of NO~2~-FA and especially their lipoxidation adducts are still a challenge that is mostly addressed by MS approaches. MS-based approaches have been extensively applied in the study of NO~2~-FA-protein adducts [@bib4], [@bib7], [@bib34], [@bib42], [@bib43], [@bib44], providing detailed structural information of these adducts both in vitro and in vivo. LC-MS and MS/MS-based proteomics approaches have been performed to characterize the NO~2~-FA protein adducts and the sites of adduction [@bib34], [@bib42], [@bib45], [@bib46], [@bib47], [@bib48]. Very recently peptide adducts were also reported for NO~2~-FA esterified in phospholipids using biomimetic in vitro studies and MS approaches [@bib49].

In this review we will discuss the formation and type of nitrated FA found in biological systems, their structure and reactivity with proteins and characterization by a MS-based proteomic and lipidomic approach that allowed to disclose possible biological roles associate with nitrated lipids-protein adducts.

2. Endogenous nitro-fatty acids {#s0010}
===============================

2.1. Chemistry and analysis {#s0015}
---------------------------

NO~2~-FA are endogenous chemical entities generated by the attack of nitric oxide (NO)-derived reactive species, collectively called reactive nitrogen species (RNS), with unsaturated fatty acids. Nitrogen dioxide (^•^NO~2~), nitronium cation (NO~2~^+^), and peroxynitrite/peroxynitrous acid, whose decomposition yields ^•^NO~2~ and hydroxyl radical (^•^OH), were reported as RNS that most frequently initiate nitration or nitroxidation reactions in biomolecules, including lipids. The prevalence and the yield of one process of these processes over the others are dependent on the oxygen levels, concentration of ROS versus RNS, the presence of secondary target molecules (scavengers, thiols, and transition metals), pH, and the partition between hydrophilic and hydrophobic milieu in cellular compartments [@bib50]. The mechanism of FA nitration and nitroxidation in biological systems is not yet wholly undisclosed, and there are some alternative routes to explain the generation of NO~2~-FA ([Fig. 2](#f0010){ref-type="fig"}). The free radical-induced nitration of FA mediated by ^•^NO~2~ is one of the most prominent reaction in vivo as a source of NO~2~-FA [@bib51]. The endogenous formation of NO~2~-FA during free radical-mediated nitration reactions occurs in several biological processes such as digestion [@bib52], metabolic stress, and inflammatory conditions [@bib53]. Thus NO~2~-FA were already identified in human red blood cells [@bib8], [@bib9], plasma [@bib6], [@bib8], [@bib9], [@bib10], [@bib12], urine [@bib6], [@bib7], and tissues [@bib1], [@bib2], [@bib3], [@bib4], [@bib5] at concentrations ranging from picomolar [@bib12] to micromolar [@bib6]. Dietary sources of nitrite can also leads to the generation of NO~2~-FA via acid-catalyzed nitration reactions [@bib52], [@bib54], [@bib55], [@bib56]. Recently, NO~2~-FA were also reported in plants, fresh olives, and in extra virgin olive oil [@bib56], [@bib57], which are considered external sources of NO~2~-FA and can contribute to rising the endogenous levels of NO~2~-FA [@bib58].Fig. 2Representative mechanisms of nitro-fatty acid (NO~2~-FA) formation. Radical-induced nitration of unsaturated fatty acids by nitrogen dioxide (^•^NO~2~) yields a β-nitroalkyl radical that can further react with other ^•^NO~2~ generating the nitronitrite intermediates. Further loss of nitrous acid (HNO~2~) leads to the generation of the nitroalkene derivatives also called NO~2~-FA. Electrophilic substitution at the double bond mediated by nitronium cation (NO~2~^+^) also yields NO~2~-FA.Fig. 2

The most common NO~2~-FA identified in vivo were the nitrated forms of the nitro-oleic acid (NO~2~-OA), nitro-linoleic acid (NO~2~-LA), and nitro-conjugated linoleic acid (NO~2~-cLA) [@bib6], [@bib8], [@bib9]. However, the reaction of RNS with fatty acids can lead to the generation of several nitroalkene derivatives of other fatty acids, such as the nitro-palmitoleic acid (NO~2~-POA), nitro linolenic acid (NO~2~-LNA), nitro-arachidonic acid (NO~2~-AA), nitro eicosapentaenoic acid (NO~2~-EPA), and nitro-docosahexaenoic acid (NO~2~-Dha) [@bib6], [@bib8], [@bib38], [@bib51]. Different stereo or positional isomers of NO~2~-FA were detected in vitro and in biological samples [@bib6], [@bib8], [@bib38], as represented in [Fig. 3](#f0015){ref-type="fig"}, [Fig. 4](#f0020){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"} and [Table 1](#t0005){ref-type="table"}.Fig. 3Proposed structures for nitro-oleic (NO~2~-OA) and nitro-linoleic acids (NO~2~-LA), with assignment of their different positional isomers, which were previously detected in in vitro studies and/or biological samples.Fig. 3Fig. 4Proposed structures for nitro arachidonic acid (NO~2~-AA), with assignment of its different positional isomers, which were previously detected in in vitro studies and/or biological samples.Fig. 4Fig. 5Proposed structures for nitro-docosahexaenoic acid (NO~2~-DHA), with assignment of its different positional isomers, which were previously detected in in vitro studies and/or biological samples.Fig. 5Table 1Nitro-fatty acids identified in biological samples and *in vitro* mimetic model systems.Table 1***In vitro*****mimetic model systemsNO**~**2**~**-FAIsomerExperimental modelMethodRef.Nitro-oleic acid (NO**~**2**~**-OA)**NO~2~-OA9-NO~2~-OAGastric juice artificial + NO~2~^−^C18-HPLC-ESI-MS and MS/MS in a API 4000 triple quadrupole and LTQ Orbitrap Velos[@bib56]10-NO~2~-OAPancreatic lipase-digested EVOONO~2~-OAMPO + H~2~O~2~ + NO~2~^−^C18-HPLC-ESI-MS and MS/MS in a hybrid triple quadrupole-linear ion trap (4000 Q-Trap)[@bib6]ONOO^−^NO~2~^−^ in acidic conditionsNO~2~-OA9-NO~2~-OA^●^NO~2~C18-HPLC-ESI-MS and MS/MS in API 2000 triple quadrupole[@bib80]10-NO~2~-OA**Nitro-linoleic acid (NO**~**2**~**-LA)**NO~2~-LA9-NO~2~-LAGastric juice artificial + NO~2~^−^C18-HPLC-ESI-MS and MS/MS in an API 4000 triple quadrupole and LTQ Orbitrap Velos[@bib56]10-NO~2~-LA12-NO~2~-LAPancreatic lipase-digested EVOO13-NO~2~-LANO~2~-LANO~2~^−^ in acidic conditionsC18-HPLC-ESI-MS and MS/MS in a Quattro triple quadrupole[@bib10]**Nitro-conjugated linoleic acid (NO**~**2**~**-cLA)**NO~2~-cLA8-NO~2~-cLAGastric juice artificial + NO~2~^−^C18-HPLC-ESI-MS and MS/MS in an API 4000 triple quadrupole and LTQ Orbitrap Velos[@bib56]9-NO~2~-cLA11-NO~2~-cLAPancreatic lipase-digested EVOO12-NO~2~-cLANO~2~-cLA9-NO~2~-cLAMPO + H~2~O~2~ + NO~2~^−^C18-HPLC-ESI-MS and MS/MS in an API 5000 triple quadrupole, API Q-Trap 4000, and Velos Orbitrap[@bib3]ONOO^−^12-NO~2~-cLA^●^NO~2~NO~2~-cLANO~2~-cLAPhotocontrollable peroxynitrite donor 2,3,5,6-tetramethyl-4- (methylnitrosoamino)phenol (P-NAP)ESI-MS and MS/MS in a hybrid triple quadrupole-linear ion trap (4000 Q-Trap)[@bib38]Multiple nitro, nitroso, and nitroxidized derivatives**Cholesteryl-nitro linoleic acid (Chol-NO**~**2**~**-LA)**Chol-NO~2~-LANO~2~^−^ in acidic conditionsC18-HPLLC-ESI/MS/MS in a Quattro II triple quadrupole[@bib9]Chol-NO~2~-LANO~2~^−^ in acidic conditionsESI--MS and MS/MS in a 2000 Q-Trap[@bib66]C18-HPLC-ESI--MS and MS/MS in a 2000 Q-Trap**Nitro-arachidonic acid (NO**~**2**~**-AA)**NO~2~-AA^●^NO~2~C18-HPLC-ESI-MS and MS/MS in an Esquire ion trap[@bib26]NO~2~-AA9-NO~2~-AANO~2~^−^ in acidic conditionsC18-HPLC-ESI-MS and MS/MS in a hybrid quadrupole-linear ion trap[@bib51]12-NO~2~-AA14-NO~2~-AA15-NO~2~-AA**Biological samplesNitro-palmitoleic acid (NO**~**2**~**-POA)**NO~2~-POAHuman plasma and urineC18-HPLC-ESI-MS and MS/MS in a hybrid triple Q-linear ion trap (4000 Q-Trap)[@bib6]**Nitrohydroxy-palmitoleic acid (NO**~**2**~**OH-POA)**NO~2~OH-POAHuman plasma and urineC18-HPLC-ESI-MS and MS/MS in a hybrid triple Q-linear ion trap (4000 Q-Trap)[@bib6]**Nitro-oleic acid (NO**~**2**~**-OA)**NO~2~-OAHuman red cells, plasma and urineC18-HPLC-ESI-MS and MS/MS in a hybrid triple Q-linear ion trap (4000 Q-Trap)[@bib6]NO~2~-OA9-NO~2~-OAMyocardial heart tissue from a murine model of focal myocardial ischemia/reperfusionC18-HPLC-ESI MS/MS[@bib1]10-NO~2~-OANO~2~-OANO~2~-OA and β-oxidation metabolitesNO~2~-OA acute intravenous treatment of mice with LPS-induced inflammationC18-HPLC-ESI-MS/MS in an API 5000 triple quadrupole[@bib107]NO~2~-OANO~2~-OA and its metabolic derivativesHuman and rat urine after intravenous administration of NO~2~-OAC18-HPLC-ESI-MS and MS/MS in a LTQ Velos Orbitrap and API 5000 triple quadrupole[@bib61]NO~2~-OANO~2~-OA and its metabolic derivativesMitochondrial extracts from rat hearts after ischemia-reperfusionBME trans-nitroalkylation + C18-HPLC-ESI-MS and MS/MS in a 4000 Q trap hybrid triple quadrupole-linear ion trap[@bib62]Dinitro-OARat cardiomyocytes treated with peroxynitrite donor 3-C18-HPLC-ESI-MS and MS/MS in a hybrid triple quadrupole-linear ion trap (4000 Q-Trap)[@bib38]morpholinosydnonimine (SIN-1)NO~2~-OANO~2~-OA and its Saturation, DesaturationPlasma from NO~2~-OA-treated miceC18-HPLC-ESI MS/MS coupled to an API 4000 hybrid triple quadrupole or API 5000 triple quadrupole[@bib59]β-oxidation metabolic derivativesNO~2~-OANO~2~-OA saturation derivativesNO~2~-OA-treated BAEC cellsC18-HPLC-ESI MS/MS coupled to an API 4000 hybrid triple quadrupole or API 5000 triple quadrupole[@bib59]NO~2~-OANO~2~-OA and its derivativesLiver lipid extracts from NO~2~-OA-treated miceC18-HPLC-ESI MS/MS coupled to an API 4000 hybrid triple quadrupole or API 5000 triple quadrupole[@bib59]**Nitrohydroxy-oleic acid (NO**~**2**~**OH-OA)**NO~2~OH-OAHuman red cells, plasma and urineC18-HPLC-ESI-MS and MS/MS in a hybrid triple Q-linear ion trap (4000 Q-Trap)[@bib6]**Nitro-linoleic acid (NO**~**2**~**-LA)**NO~2~-LAMyocardial heart tissue from a murine model of focal myocardial ischemia/reperfusionC18-HPLC-ESI MS and MS/MS[@bib1]NO~2~-LAHuman plasma and urineC18-HPLC-ESI-MS and MS/MS in a hybrid triple Q-linear ion trap (4000 Q-Trap)[@bib6]NO~2~-LAHuman blood plasmaC18-HPLC-ESI-MS and MS/MS in a Quattro triple quadrupole[@bib10]NO~2~-LA9-NO~2~-LAHuman red cell membranes and plasmaC18-HPLC-ESI-MS and MS/MS in a hybrid triple Q-linear ion trap[@bib8]12-NO~2~-LANO~2~-LANO~2~-LA and its metabolic derivativesMitochondrial extracts from rat hearts after ischemia-reperfusionBME trans-nitroalkylation + C18-HPLC-ESI-MS and MS/MS in a 4000 Q trap hybrid triple quadrupole-linear ion trap[@bib62]**Nitrohydroxy-linoleic acid (NO**~**2**~**OH-LA)**NO~2~OH-LAMyocardial heart tissue from a murine model of focal myocardial ischemia/reperfusionC18-HPLC-ESI MS and MS/MS[@bib1]NO~2~OH-LAHuman plasma and urineC18-HPLC-ESI-MS and MS/MS in a hybrid triple Q-linear ion trap (4000 Q-Trap)[@bib6]**Nitrokto-linoleic acid (NO**~**2**~**-oxo-LA)**NO~2~-oxo-LAMyocardial heart tissue from a murine model of focal myocardial ischemia/reperfusionC18-HPLC-ESI MS/MS[@bib1]**Nitro-conjugated linoleic acid (NO**~**2**~**-cLA)NO**~**2**~**-cLA**Plasma and vaginal lavages after cLA inoculation in the vaginal lumen from mice infected intravaginally with HSV-2C18-HPLC-MS/MS in a 6500+ Q-trap or a API 5000[@bib16]**Nitro-linolenic acid (NO**~**2**~**OH-LNA)**NO~2~-LNAHuman plasma and urineC18-HPLC-ESI-MS and MS/MS in a hybrid triple Q-linear ion trap (4000 Q-Trap)[@bib6]**Nitrohydroxy-linolenic acid (NO**~**2**~**OH-LNA)**NO~2~OH-LNAHuman plasma and urineC18-HPLC-ESI-MS and MS/MS in a hybrid triple Q-linear ion trap (4000 Q-Trap)[@bib6]**Nitro-arachidonic acid (NO**~**2**~**-AA)**NO~2~-AAHuman plasma and urineC18-HPLC-ESI-MS and MS/MS into a hybrid triple Q-linear ion trap (4000 Q-Trap)[@bib6]NO~2~-AARat cardiomyocytes treated with peroxynitrite donor 3-C18-HPLC-ESI-MS and MS/MS in a hybrid triple quadrupole-linear ion trap (4000 Q-Trap)[@bib38]morpholinosydnonimine (SIN-1)**Nitrohydroxy-arachidonic acid (NO**~**2**~**OH-AA)**NO~2~OH-AAHuman plasma and urineC18-HPLC-ESI-MS and MS/MS in a hybrid triple Q-linear ion trap (4000 Q-Trap)[@bib6]**Nitro-Eicosapentaenoic acid (NO**~**2**~**-EPA)**NO~2~-EPAHuman plasma and urineC18-HPLC-ESI-MS and MS/MS in a hybrid triple Q-linear ion trap (4000 Q-Trap)[@bib6]**Nitrohydroxy- Eicosapentaenoic acid (NO**~**2**~**OH-EPA)**NO~2~OH-EPAHuman plasma and urineC18-HPLC-ESI-MS and MS/MS in a hybrid triple Q-linear ion trap (4000 Q-Trap)[@bib6]**Nitro-Docosahexaenoic acid (NO**~**2**~**-DHA)**NO~2~-DHA and dinitro-DHARat cardiomyocytes treated with peroxynitrite donor 3-C18-HPLC-ESI-MS and MS/MS in a hybrid triple quadrupole-linear ion trap (4000 Q-Trap)[@bib38]morpholinosydnonimine (SIN-1)**Nitrohydroxy-Docosahexaenoic acid (NO**~**2**~**-DHA)**NO~2~OH-DHARat cardiomyocytes treated with peroxynitrite donor 3-C18-HPLC-ESI-MS and MS/MS in a hybrid triple quadrupole-linear ion trap (4000 Q-Trap)[@bib38]morpholinosydnonimine (SIN-1)**Nitrohydroxy-Docosapentaenoic acid (NO**~**2**~**OH-DPA)**NO~2~OH-DPARat cardiomyocytes treated with peroxynitrite donor 3-C18-HPLC-ESI-MS and MS/MS in a hybrid triple quadrupole-linear ion trap (4000 Q-Trap)[@bib38]Morpholinosydnonimine (SIN-1)**Nitro-conjugated linoleic acid (NO**~**2**~**-cLA)**NO~2~-cLA9-NO~2~-cLAPancreatic lipase-digested EVOOC18-HPLC-ESI-MS and MS/MS in an API 4000 triple quadrupole and LTQ Orbitrap Velos[@bib56]12-NO~2~-cLANO~2~-cLA9-NO~2~-cLAUrine of healthy humansC18-HPLC-ESI-MS and MS/MS in a LTQ Velos Orbitrap and AB 5000 or API4000 Q-trap triple quadrupole[@bib7]12-NO~2~-cLAβ-oxidation-metabolic derivatives of NO~2~-cLANO~2~-cLA9-NO~2~-cLARodents urine, plasma, and tissues (stomach, small intestine, colon, liver) after supplementation with cLA + NO~2~^−^ and gastric acidificationC18-HPLC-ESI-MS and MS/MS in an API 5000 triple quadrupole, API Q-Trap 4000, and Velos Orbitrap[@bib3]Rodents liver and cardiac mitochondria incubated with NO~2~^−^ in acidic conditions12-NO~2~-cLARodents cardiac tissue under ischemia-reperfusionRaw 264.7 macrophages stimulated with LPS/IFN*γ*Healthy human plasmaNO~2~-cLA9-NO~2~-cLARAW264.7 macrophages stimulated with LPS/IFN*γ* and M1, M2 and M0 polarized bone marrow-derived macrophages (BMDM) treated with cLAC18-HPLC-ESI-MS and MS/MS in an API 5000 or a Q-Trap 6500+ and LTQ Velos Orbitrap[@bib13]12-NO~2~-cLAReduction and β-oxidation-metabolic derivativesMice Peritoneal exudates after zymosan-A induced peritonitisand cLA supplementationNO~2~-cLANO~2~-cLA and β-oxidation-metabolic derivativesUrine and plasma healthy humans after ingestion of nitrite, nitrate and cLAC18-HPLC-ESI-MS and MS/MS in a 5000 triple quadrupole[@bib58]**Cholesteryl-nitro linoleic acid (Chol-NO**~**2**~**-LA)**Chol-NO~2~-LAHuman blood plasma and lipoproteins from normolipidemic/healthy subjectsC18-HPLLC-ESI/MS/MS in a Quattro II triple quadrupole[@bib9]Chol-NO~2~-LAJ774.1 macrophages timulated with LPS/IFN*γ*C18-HPLC-ESI--MS and MS/MS in a 2000 Q-Trap[@bib66]

Nevertheless, the recovery of NO~2~-FA from biological samples, together with their detection and accurate quantification is a challenge due to their low concentration, stability issues, metabolism (β-oxidation and saturation/desaturation reactions) [@bib59], reactivity with proteins [@bib59] and esterification [@bib39], [@bib40], [@bib41], and different distribution among tissues and biofluids [@bib6], [@bib12]. In line with these limitations, there has been an effort for the development of specific, standardized and reproducible methodologies of sample preparation and sensitive analytical approaches. The advent of more sensitive and sophisticated instruments, allied with the possibility of high-throughput analysis prompted by MS-based approaches, combined or not with liquid chromatography (LC-MS), has been the selected tool for the identification, structural characterization and quantification of free NO~2~-FA. Indeed, the detection of these lipids is an indication to disclose the bioactive properties of these nitrated derivatives. The progress in the field of MS-based approaches enabled the discovery of NO~2~-FA and contributed to the knowledge of NO~2~-FA biological roles giving information on the structure-function relationships [@bib60]. The development of improved sample preparation techniques, chromatographic separations, high-resolution instruments with great sensitivity, and innovative tools raised the possibility of detection, structural characterization and quantification of nitro lipids in human samples and animal models both under physiological and pathological conditions [@bib1], [@bib3], [@bib4], [@bib8], [@bib59], [@bib61], [@bib62], and also in plants [@bib56] as summarized in [Table 1](#t0005){ref-type="table"}. The identification of NO~2~-FA by MS is based on the detection of specific mass shifts compared to non-modified fatty acid (FA+45 Da). Using MS-based approaches, NO~2~-FA are preferentially analyzed in negative-ion mode as \[M-H\]^−^ ions [@bib3], [@bib63]. However, positive-ion mode ionization can also occur, and NO~2~-FA can also be identified as \[M+H\]^+^ [@bib26], \[M+Li\]^+^ [@bib51], \[M+NH~4~\]^+^ [@bib9], [@bib41], and \[M+Na\]^+^ ions [@bib9]. Tandem mass spectra acquired both in positive- and negative-ion mode provides information that allows the structural characterization of NO~2~-FA [@bib8], [@bib38], [@bib51], [@bib63], [@bib64]. The fragmentation pattern of NO~2~-FA under tandem MS (MS/MS) conditions includes the typical neutral losses of 47 Da (HNO~2~) and product ions formed by cleavage of the hydrocarbon chain in the vicinity of the NO~2~ group that allow assigning this modified FA. The differentiation of isomers can be addresses by the identification of reporter fragment ions that are formed by cyclization, followed by heterolytic carbon chain fragmentation, which allows pinpointing the correct position of the NO~2~ group [@bib2], [@bib63]. These product ions have been used as diagnostic ions broadly employed for targeted analysis and quantitation of specific NO~2~-FA using reversed phase LC-MS/MS approaches, in biomimetic systems and in cells, tissues and biofluids [@bib3], [@bib6], [@bib8], [@bib9], [@bib10], [@bib12], [@bib17], [@bib38], [@bib59], [@bib65], [@bib66]. Structural information gathered by using MS studies can be further confirmed by infrared and nuclear magnetic resonance analysis for the confirmation of the functional groups and the final structure [@bib6], [@bib9], [@bib10], [@bib30], [@bib31], [@bib51].

The generation of NO~2~-FA can be considered as the first step of nitration reactions. These species can be precursors of other nitrated and nitroxidized species because NO~2~-FA can undergo additional reaction with ROS and RNS to be further nitrated, leading to the formation of nitroso, dinitroso, nitronitroso, di and trinitro species, or oxidized generating the assorted nitroxidized species as nitrohydroxy, nitrohydroperoxy, nitro-epoxy and nitro-keto ([Table 1](#t0005){ref-type="table"}) [@bib3], [@bib6], [@bib8], [@bib26], [@bib54], [@bib64]. All of these derivatives were already identified by (LC)-MS and characterized by (LC)-MS/MS [@bib1], [@bib6], [@bib9], [@bib38]. In fact, the great sensitivity of MS-based approaches allowed to identify both nitro and nitrohydroxy derivatives of palmitoleic, oleic, linoleic, linolenic, arachidonic and eicosapentaenoic acids in human plasma and urine [@bib6]. However by far the NO~2~-FA are the most studied mostly because, in opposition to other nitrated and nitroxidized FA, they are electrophilic molecules with great capability to react with protein with the formation of lipoxidation adducts.

2.2. Biological roles of nitro-fatty acids as new metabolic mediators, signaling molecules, and new therapeutic drugs candidates {#s0020}
--------------------------------------------------------------------------------------------------------------------------------

NO~2~-FA have raised the interest of the scientific community in last years, mainly because of their biological roles as key mediators in physiological and pathophysiological processes, as demonstrated in a variety of preclinical animal models of disease and in plants [@bib2], [@bib5], [@bib13], [@bib15], [@bib20], [@bib28], [@bib32], [@bib34], [@bib45], [@bib56]. They were assigned as biologically relevant and putative signaling molecules in cardiovascular disease [@bib28], [@bib33], myocardial ischemia/reperfusion and ischemia preconditioning [@bib1], [@bib2], [@bib24], nephropathy [@bib24], renal ischemia/reperfusion [@bib24], diabetes and metabolic syndrome [@bib14], pulmonary inflammation [@bib15], [@bib67] and chronic inflammatory disease [@bib65]. NO~2~-FA reach endogenous levels that allow them to mediate pivotal signaling actions as cytoprotective and pro-survival players [@bib2], [@bib34], [@bib35], [@bib36], [@bib37], and based on their pleiotropic actions, NO~2~-FA has emerged as potential therapeutic agents with high potential for therapeutic use ([Table 2](#t0010){ref-type="table"}). In fact, NO~2~-FA already undergo clinical trials [@bib68]. The 10-NO~2~-OA (CXA-10) demonstrated promising pharmacokinetic and pharmacodynamics characteristics during preclinical experiments [@bib61], [@bib68], [@bib69]. CXA-10 is currently in phase II clinical trials for the treatment of chronic inflammatory and metabolic-related diseases, namely focal segmental glomerulosclerosis and pulmonary arterial hypertension, since it demonstrated beneficial effects when administrated via intravenous injections or through ingestion [@bib61], [@bib68], [@bib69].Table 2Modulation of target signaling pathways by NO~2~-FA and related biological properties.Table 2**Anti-inflammatory**-NF-kB ↓ [@bib1], [@bib13], [@bib15], [@bib21], [@bib23], [@bib46], [@bib60], [@bib66], [@bib86], [@bib90], [@bib108]-TL4R signaling ↓ [@bib107]-PG H synthase ↓ [@bib86], [@bib109]-5-LOX ↓ [@bib45]-STAT1 ↓ [@bib87], [@bib92]-Cytokine production ↓[@bib1], [@bib5], [@bib7], [@bib13], [@bib20], [@bib21], [@bib23], [@bib24], [@bib66], [@bib86], [@bib110], [@bib111], [@bib112]-MPO ↓ [@bib24]-Leukocyte recruitment, adhesion and infiltration ↓ [@bib13], [@bib23], [@bib24], [@bib87], [@bib108], [@bib112]-iNOS ↓ [@bib13], [@bib24], [@bib36], [@bib51], [@bib60], [@bib66], [@bib86], [@bib112]-COX-2 ↓ [@bib112]-PGE~2~ ↓ [@bib112]-Leukocytes number and activity ↓ [@bib5], [@bib13], [@bib18], [@bib108]-TNF-α ↓ [@bib23]-Xanthine oxidoreductase (XOR) ↓ [@bib73]-MKP-1 ↑ [@bib92]-PPARγ ↑ [@bib6], [@bib15], [@bib21], [@bib65], [@bib100]-TRPA-1 ↑ [@bib98]-CD36 expression ↑ [@bib100]-Heme oxygenase 1 (HO-1) ↑ [@bib17], [@bib19], [@bib22], [@bib23], [@bib60], [@bib66], [@bib67], [@bib89], [@bib93]-STING ↓ [@bib16]-PDI ↓ [@bib95]-NADPH oxidase (NOX 2) ↓ [@bib24], [@bib74], [@bib113]**Vasorelaxation**-Nitric oxide ↑ [@bib29], [@bib30], [@bib31], [@bib51]-eNOS ↑ [@bib114]-Ang II-induced vasoconstriction ↓ [@bib28]**Antioxidant**-Lipid peroxidation ↓ [@bib71], [@bib86]-Nrf2 ↑ [@bib13], [@bib15], [@bib22], [@bib46], [@bib60], [@bib88]-HO-1 ↑ [@bib17], [@bib19], [@bib22], [@bib60], [@bib66], [@bib89]-Reduction of protein nitration and oxidation [@bib87]-Heat shock response (HSP) proteins [@bib22]-XOR ↓ [@bib73]-NOX 2 ↓ [@bib24], [@bib74], [@bib113]-O2^●-^, ONOO- and NO production ↓ [@bib36], [@bib48], [@bib86], [@bib108], [@bib111], [@bib113]**Anti-hypertensive**-AT1R ↓ [@bib28]-sEH ↓ [@bib32]-Smooth muscle cell proliferation ↓ [@bib111]-Prostaglandin F2↓ [@bib111]-Differentiation of myofibroblast through Smad2 ↓ [@bib113]**Anti-hyperglycemic**-PPARγ ↑ [@bib6], [@bib28], [@bib100]-Glucose uptake ↑ [@bib110]-Insulin sensitivity ↑ [@bib6], [@bib28], [@bib100]**Anti-thrombotic**-Platelets activation and clotting ↓ [@bib18], [@bib31], [@bib33]-Platelet production of thromboxane↓ [@bib109]-Thrombin-induced aggregation ↓ [@bib33]-PGHS ↓ [@bib109], [@bib115], [@bib116]**Cytoprotective**-ANT1 ↑ [@bib2], [@bib34]-UCP-2 ↑ [@bib2]-Mitochondrial dysfunction ↓ [@bib36], [@bib37]-Mitochondrial respiratory complex ↑ [@bib48]-Metabolic shift ↑ [@bib48]**Anti-tumorogenic**-Tumor cell proliferation, migration and invasion↓ [@bib90]

The biological actions of NO~2~-FA are mediated via a) decay reactions and transduction of nitric oxide (^•^NO) signaling actions [@bib29], [@bib70], since NO~2~FA can be considered NO donor; b) via receptor-dependent and c) via electrophilic adduction reactions to proteins [@bib42], with formation of lipoxidation adducts. All these processes mediate important and specific signaling roles. These signaling actions are summarized in [Table 2](#t0010){ref-type="table"}. Nitric oxide release by NO~2~-FA has been associated with potential antioxidant properties through inhibition of lipid peroxidation process [@bib71]. Additionally, the release of ^•^NO by both NO~2~-FA and nitrohydroxy FA derivatives has also been related with vasorelaxation properties of these nitrated lipid [@bib26], [@bib29], [@bib30], [@bib31], [@bib51]. The nitro derivatives of arachidonic acid, NO~2~-AA and nitrohydroxy-AA, were also reported to be able to release ^•^NO and thus to induce cGMP-dependent vasorelaxation in rat aortic ring in an endothelium-independent manner [@bib26], [@bib31], [@bib51]. NO~2~-LA, NO~2~-cLA and nitrohydroxy-LA promoted vessel relaxation via cGMP-dependent and endothelial-independent manner in pre-constricted rat aortic rings [@bib29], [@bib30]. Nevertheless, the ^•^NO release by nitro lipids remains a controversial issue, and at some level, considered of minor relevance at endogenous levels [@bib28], [@bib29], [@bib51], [@bib70], [@bib72]. Actually, ^•^NO signaling actions mediated by NO~2~-FA mainly occurs via cGMP-independent mechanisms. NO~2~-FA modulates endothelial (eNOS) and inducible nitric oxide synthase (iNOS) gene expression and activity and consequently the eNOS- and iNOS-mediated ^•^NO generation and reactions. Also, NO~2~-FA modulates a broad array of signaling pathways that culminates with the downstream activation or inactivation of ^•^NO signaling [@bib67], [@bib73], [@bib74].

The covalent adduction to key proteins propelled by the electrophilic character of NO~2~-FA seems to be the most prominent mechanism by which these nitro lipids spread their modulatory and protective actions. The identification and characterization of these NO~2~-FA-protein adducts in distinct biological conditions have been achieved by reversed phase LC-MS-based proteomics approaches [@bib28], [@bib42], [@bib56], [@bib59], [@bib75], [@bib76]. This topic will be discussed in more detail in the next section.

As endogenous molecules, NO~2~-FA undergo a series of metabolic, trafficking and clearance pathways that influences the regulation of activity, half-life and levels of free NO~2~-FA. Protein adduction and esterification in complex lipids [@bib70], [@bib77], [@bib78] are considered as reservoirs of NO~2~-FA, allowing to regulate their endogenous levels [@bib70], [@bib77], [@bib78]. NO~2~-FA--protein adducts are reversible in biological systems [@bib59], [@bib73], [@bib79] and NO~2~-FA esterified forms can be hydrolyzed and mobilized by esterases and lipases, allowing NO~2~-FA to return to free active forms [@bib70], [@bib80]. NO~2~-FA can be metabolized via β-oxidation that mediates the formation of shorter and more polar electrophilic species [@bib59] that retains the electrophilic power, but also to inactive nitroalkane species [@bib7], [@bib59]. In fact, in humans and rodents, the bio-elimination pathways of 10-NO~2~-OA involves the generation of a series of shorter metabolites that were detected in urine using C18-HPLC-ESI-MS and MS/MS using both LTQ Velos Orbitrap and API 5000 triple quadrupole instruments [@bib61]. However, the electrophilic functionality of NO~2~-FA is irreversibly inactivated after reduction and conversion to the correspondent nitroalkane derivative by the nitroalkene saturase prostaglandin reductase-1 [@bib81]. Both saturation and desaturation of the double bond of NO~2~-FA are related with the generation of non-electrophilic NO~2~-FA [@bib59], which are nitro derivatives without signaling abilities. Adduction to peptides or proteins seems to have other proposes, such as the case of conjugation with GSH, which increases the urinary excretion rate of NO~2~-FA excreted in urine [@bib82]. Incorporation of NO~2~-FA into lipoproteins is another way for NO~2~-FA to enter in circulation and to be systemically distributed among tissues. The modulation of all of these diverse pathways will impact the potential reactivity, the efficacy of signaling actions and behavior of these nitration products.

The signaling actions of NO~2~-FA are also mediated through the modulation of the structure and regulation of the expression and activity of anti- and pro-inflammatory proteins, heat shock proteins and phase II antioxidant response proteins. The capability of NO~2~-FA to react with specific peptides and proteins determines the role of this nitrated lipids in redox regulation with consequence in cell signaling, as will be described in the following section.

3. Nitro-fatty acids and protein lipoxidation adducts {#s0025}
=====================================================

3.1. Main target and biological significance of PTM by nitro-fatty acids {#s0030}
------------------------------------------------------------------------

NO~2~-FA are electrophilic compounds, able to react via reversible Michael addition with nucleophiles within key proteins, leading to the formation of lipid-protein adducts (lipoxidation) in a process generally denominated nitroalkylation [@bib83], [@bib84]. The target nucleophiles in peptides and proteins include the deprotonated thiolate group of cysteine and the nucleophilic amino group of the imidazole moiety of histidine or the amino groups of lysine and arginine [@bib83], [@bib84], [@bib85]. The high electronegative olefinic NO~2~ group facilitate the addition to the double bond of the unsaturated hydrocarbon chain of NO~2~-FA. This addition generates an important positive density of charge in the methylenic β-carbon adjacent to the nitration site. The oxygens of the NO~2~ group withdraw electrons and the double bond is rearranged over the C--N bond, generating a carbocation. This conjugation makes the β-carbon adjacent to the NO~2~ group electron poor and with potential reactivity. The NO~2~-FA-protein covalent adducts generated during the nitroalkylation process are reversible, which seems to be related with the possibility of redox regulation [@bib59], [@bib73], [@bib79] and thus can be associated with the apparent lack of toxicity of these modified lipids. All of the aforementioned characteristics make NO~2~-FA as promising pharmacological compounds. In fact, pre-clinical and human trials has demonstrated the NO~2~-FA favorable pharmacokinetics and safety.

The formation of NO~2~-FA adducts with proteins is considered a key PTM of proteins. This modification of functionally-relevant proteins can modulate the patterns of gene expression programs, transcription factors function, enzyme function and activity, metabolic and inflammatory responses, and cell signaling networks [@bib50], [@bib59], [@bib73], [@bib84]. This lead to a series of downstream signaling events that are intrinsically related to the biological signaling roles of NO~2~-FA [@bib2], [@bib6], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31], [@bib32], [@bib33], [@bib34], [@bib35], [@bib36], [@bib37], [@bib61], [@bib74], [@bib75], [@bib86], [@bib87], [@bib88], [@bib89], [@bib90] ([Table 2](#t0010){ref-type="table"}). The activation of several of these pathways are considered essential for restoring the homeostasis and the redox balance and makes NO~2~-FA promising pharmacological compounds [@bib91].

There are several proteins reported to be targets of NO~2~-FA electrophilic reactivity, for example, the p65 subunit of NF-κB [@bib1], [@bib23], [@bib92], heme oxygenase-1 (HO-1) [@bib17], [@bib19], [@bib22], [@bib67], [@bib89], [@bib93], mitogen-activated protein kinase (MAPK) phosphatase 1 (MPK-1) [@bib92], Kelch-like ECH-associated protein 1 (Keap 1) [@bib17], [@bib22], [@bib46], [@bib88], metalloproteinases (MMP-7 and MMP-9) [@bib75], glyceraldehyde-3-phosphate dehydrogenase (GAPDH) [@bib42], [@bib94], protein disulfide isomerase (PDI) [@bib95], and transient receptor potential (TRP) channels [@bib96], [@bib97], [@bib98], [@bib99] ([Table 3](#t0015){ref-type="table"}). NO~2~-FA can also conduct their biological signaling roles by a receptor-dependent signaling action and peroxisome proliferator-activated receptor gamma (PPARγ) is one of the main targets, which is a significant route for the anti-inflammatory effect associated with NO~2~-FA derivatives [@bib6], [@bib23], [@bib47], [@bib65], [@bib93], [@bib100], [@bib101], [@bib102].Table 3Nitro-fatty acids lipoxidation adducts identified in biological samples and *in vitro* mimetic model systems by using mass spectrometry-based approaches.Table 3**Protein/peptideModel systemMethodMolecular mechanism signaling actionBiological roleRef.Nitro-oleic acid (NO**~**2**~**-OA)**CysteineIncubation of NO~2~-OA and cysteineC18-HPLC-MS and MS/MS in a triple quadrupole API 4000[@bib56]Incubation of NO~2~-OA and cysteineC18-HPLC-MS and MS/MS in a triple quadrupole[@bib43]Whole olives, mesocarp and peelC18-HPLC-MS and MS/MS in a triple quadrupole API 4000[@bib56]GSHNO~2~-OA-Cys adduct generation after incubation between NO~2~-OA and GSHBME trans-nitroalkylation + C18-HPLC-ESI-MS and MS/MS in a Q trap 4000[@bib62]NO~2~-OA-Cys adduct generation after incubation between NO~2~-OA and GSH(BME trans-nitroalkylation +) C18-HPLC-ESI-MS and MS/MS in a hybrid triple quadrupole API 4000 or API 5000 triple quadrupole[@bib59]Plasma from NO~2~-OA-treated mice(BME trans-nitroalkylation) C18-HPLC-ESI-MS and MS/MS in a hybrid triple quadrupole API 4000 or API 5000 triple quadrupole[@bib59]NO~2~-OA-Cys adduct generation after incubation between NO~2~-OA and GSHESI-MS in LCQ ion trap[@bib42]Tryptic digestion + C18-HPLC-ESI-MS and MS/MS in an ESI-LCQ ion trapC18-HPLC-ESI-MS/MS in a Q-Trap 4000Red blood cells obtained from healthy humansC18-HPLC-ESI-MS/MS in a Q-Trap 4000Translocation to membraneRegulation of enzyme function, cell signaling, and protein trafficking[@bib42]GAPDHCytosolic and membrane-associated protein fractions from red blood cells obtained from healthy humansSDS-PAGE under non-reducing and denaturing conditions + Tryptic digestion + C18-nanospray LC-MS and MS/MS in a LTQ ion trapTranslocation to membraneRegulation of enzyme function, cell signaling, and protein trafficking[@bib42]Cys149His303            GAPDHIncubation of NO~2~-OA and GAPDHMALDI-TOF MS (Voyager DE PRO system)[@bib42]Cys149C18-HPLC-MS in a LTQ ion trapCys153Tryptic digestion and MALDI-TOF MS (Voyager DE PRO system)Cys244His108Tryptic digestion + C18-HPLC-ESI-MS in an ESI-LCQ ion trapHis134His327Tryptic digestion + C18-nanospray LC-MS and MS/MS in a LTQ ion trapGAPDHIncubation of NO~2~-OA and GAPDHElectrophoresis under reducing conditions + BME trans-nitroalkylation + C18-HPLC-ESI-MS and MS/MS in a 4000 Q trap hybrid triple quadrupole-linear ion trap[@bib62]5-LOXIncubation of NO~2~-OA and human recombinant 5-LOXTryptic digestion and C18-nanoHPLC-ESI-MS and MS in an Orbitrap XLIrreversible inhibition of 5-LOX activity andAnti-inflammatory[@bib45]Cys416**Cys418**His125His360Incubation of NO~2~-OA and human polymorphonuclear leukocytes (PMNL) (intact and cell lysates)Prevention of lung injury and systemic immune responsesHis362His367His372NO~2~-OA treatment in murine model of LPS-induced inflammation (lung injury and cellular infiltration)His432Keap1Incubation of NO~2~-OA and recombinant Keap1Tryptic digestion C18-HPLC-MS and MS/MS in a LTQRelease of Nrf2 tracsription factor to the nucleous for induction of expression of antioxidant phase II enzymesAntioxidant[@bib46]Cys38Cys151Cys226**Cys273**Human embryonic kidney (HEK)-293T cells transfected with recombinant Keap1 and treated with NO~2~-OA**Cys288**Cys257Cys489            Catephsin SIncubation of NO~2~-OA with a synthetic Cat S peptide (Cat S23--29)C18-HPLC-MS and MS/MS in a Q Exactive Hybrid Quadrupole-OrbitrapDownregulation of Cat S expression and activityTissue Protection[@bib5](Cat S)Anti-inflammatoryCys25Fp subunit of mitochondrial complex IIIncubation of NO~2~-OA with recombinant human complex II Fp subunitTryptic digestion and C18-HPLC-MS and MS/MS in a LTQ-XLInhibition of mitochondrial respiration complex II and O~2~^●−^ productionCytoprotective[@bib48]His2His5His6Rat heart mitochondria treated with OA-NO~2~Blue native electrophoresis, BME trans-nitroalkylation, C18-HPLC-MS amd MS/MS in a hybrid triple-quadrupole linear ion trap mass spectrometer (4000 Q trap)Promotion of glycolysisAntioxidantCys9Cys14AT~1~RHEK293 cells overexpressing AT~1~R treated with NO~2~-OAImmunoprecipitation of AT~1~R from cell lysates, BME trans-nitroalkylation reaction of AT~1~R-bound NO~2~-OA, and C18-HPLC-MS and MS/MS in a 4000 Q-Trap triple quadrupoleInhibits AT~1~R-dependent vasoconstriction by reduction of heterotrimeric G-protein coupling and inhibition of IP~3~ and calcium mobilizationAnti-hypertensive[@bib28]MMP-7Incubation of NO~2~-OA with recombinant human proMMP-7 and proMMP-9C18-HPLC-ESI-MS and MS/MS in a LTQ-XLModulation of proteolytic activityAnti-inflammatory[@bib75]Cys70C18-HPLC-ESI-MS and MS/MS in a hybrid triple quadrupole-linear ion trap 4000 Q-TrapDecrease of enzyme expressionMMP-9Cys100            AlbuminPlasma from intraperitoneal NO~2~-OA-treated miceElectrophoresis under reducing conditions + BME trans-nitroalkylation + C18-HPLC-ESI-MS and MS/MS in a 4000 Q trap hybrid triple quadrupole-linear ion trap[@bib62]Plasma from NO~2~-OA-treated miceElectrophoresis + BME trans-nitroalkylation + C18-HPLC-ESI-MS and MS/MS in a hybrid triple quadrupole API 4000 or API 5000 triple quadrupole[@bib59]PPARγIncubation of NO~2~-OA with human recombinant PPARγ LBDTryptic digestion and C18-HPLC-MS and MS/MS in a LTQActivation of PPARγ-related gene expression for glucose regulation and adipogenesisAnti-hyperglycemic[@bib47]HEK 293 T cells were transfected with PPARγ and treated with NO~2~-OAImmunoprecipitation, gel electrophoresis, BME- trans-nitroalkylation and ESI-MS and MS/MS in a hybrid triple quadrupole-linear ion trap mass spectrometer (4000 Q Trap,Decrease in adipogenesis**Cys285**Increase glucose uptakeAnti-adipogenic effectHis266His323Restore insulin sensivityHis425His449            STINGIncubation human STING-transfected HEK293T cells with 10-NO~2~-OAPurification with magnetic beads, tryptic digestion and MALDI LTQDeregulation of STING palmitoylatioAnti-inflammatory[@bib16]Cys88Inhibition of STING signalingCys91Orbitrap XLInhibition the release of type I IFNHis16  **Nitro-linoleic acid (NO**~**2**~**-LA)**cysteineNO~2~-LA-Cys adduct generation after incubation between NO~2~-LA and cysteine(C18-HPLC)-ESI-MS and MS/MS in a triple quadrupole[@bib107]GSHNO~2~-LA-Cys adduct generation after incubation between NO~2~-LA and GSHESI-MS in LCQ ion trap[@bib42]C18-HPLC-ESI-MS/MS in a Q-Trap 4000NO~2~-LA-Cys adduct generation after incubation between NO~2~-LA and GSHBME trans-nitroalkylation + C18-HPLC-ESI-MS and MS/MS in a Q trap 4000[@bib62]NO~2~-LA-Cys adductC18-HPLC/ESI/MS in Micromass Quattro II triple quadrupole[@bib76]Generation after incubation between NO~2~-LA and GSHRed blood cells obtained from healthy humansC18-HPLC-ESI-MS/MS in Q-Trap 4000[@bib42]MCF7/WT and MCF7/MRP1--10 cells treated with NO2-LAC18-HPLC/ESI/MS in Micromass Quattro II triple quadrupole[@bib76]ANT1NO2-LA-treated intact perfused heartsImmunoprecipitation + SDS-PAGE + in-gel digestion tryptic digestion + ABSciex 5800 MALDI-TOF-TOF MS and MS/MSMitochondrial uncouplingCytoprotective[@bib34]Cys57  **Nitro-conjugated linoleic acid (NO**~**2**~**-cLA)**cysteineNO~2~-cLA-Cys adduct generation after incubation between NO~2~-cLA and cysteineC18-HPLC-MS and MS/MS in LTQ Velos Orbitrap and AB 5000 or API4000 Q-trap triple quadrupole[@bib7]Urine from healthy humansC18-HPLC-MS and MS/MS in LTQ Velos Orbitrap and AB 5000 or API 4000 Q-trap triple quadrupole[@bib7]NO~2~-cLA-Cys adduct generation after incubation between NO~2~-cLA and cysteineC18-HPLC-MS and MS/MS in API 5000 triple quadrupole[@bib44]Urine from healthy humansC18-HPLC-MS and MS/MS in API 5000 triple quadrupole[@bib44]**Nitro-arachidonic acid (NO**~**2**~**-AA)**PDIIncubation of human recombinat PDI with NO~2~-AAC4-HPLC-MS of intact protein in a hybrid triple quadrupole/linear ion trap mass spectrometer (Q-trap 4500)Inhibition of reductase and chaperone activity of PDIAnti-inflammatory[@bib95]digestion tryptic digestion and C18-HPLC-MS and MS/MSCys397Cys400

The nitro lipoxidation PTM of the proteins shown in the [Table 3](#t0015){ref-type="table"} have been correlated with specific biological effects. For example, nitroalkylation of the p65 subunit of NF-κB [@bib23], induction of HO-1 expression [@bib93], PPARγ modulation [@bib100], inhibition of the correct assembly of the active NADPH oxidase (NOX2) [@bib74], and inhibition of both reductase and chaperone activities of PDI and possible prevention of NOX2 activation [@bib95] have been associated with the anti-inflammatory properties of NO~2~-FA. Another important anti-inflammatory action of NO~2~-FA is attributed to their capability to induce PTM of 5-Lipoxygenase (5-LOX) limiting the inflammation induced by the 5-LOX-dependent leukotriene synthesis. This point deserves to be further explored as a potential therapeutic/pharmacological strategy due to the physiological relevance of 5-LOX, namely in inflammation [@bib45]. Induction of HO-1 and activation of Nrf2 have been correlated with protection against oxidative stress and antioxidant actions of NO~2~-FA [@bib93]. Activation of PPARγ by NO~2~-FA has also been associated with glucose uptake and anti-hyperglycemic effects [@bib100]. Inhibition of the catalytic activity of sHE was associated with anti-hypertensive properties of NO~2~-FA [@bib32]. Finally, neuroprotective effects associated with the decrease of protein aggregation were related with PTMs of α-synuclein by NO~2~-OA [@bib35].

3.2. Identification of protein-nitro-fatty acids adducts: tools and challenges {#s0035}
------------------------------------------------------------------------------

Identification of protein nitroalkylation by NO~2~-FA has been disclosed by using different experimental approaches, as crystallographic analysis [@bib100], [@bib101], western immunoblot-based assay [@bib2], [@bib23], [@bib32], [@bib34], [@bib87], spectrophotometry [@bib7], [@bib43], [@bib44], [@bib94] and MS-based approaches [@bib4], [@bib7], [@bib34], [@bib42], [@bib43], [@bib44]. However, spectrophotometry and immunoassays do not give detailed structural information and crystallography requires pure proteins, being difficult to be used in the analysis of complex biological samples.

Mass spectrometry, namely using matrix assisted laser desorption/ionization (MALDI) or electrospray (ESI) MS-based proteomics approaches, often coupled to reverse phase (RP) liquid chromatography (LC--MS), are the most suitable methods for detection and characterization of adducts formed between NO~2~-FA and proteins. *In vitro* generation of NO~2~-FA-protein adducts, in biomimetic systems, between standards of NO~2~-FA and candidate peptides or proteins has been used as strategy for the initial identification by (LC)-MS and further characterization of these adducts by MS/MS. Data obtained using these biomimetic approaches using controlled reaction conditions are more straightforward and relatively easy to analyze. This, in turn, allows to obtain knowledge on the reactivity of each individual NO~2~-FA and the typical fragmentation pathways under MS/MS needed to identify these adducts. The information gathered by tandem mass experiments concerning the typical fragmentation pathways and reporter ions can be used to identify these lipoxidation products in complex biological samples by using MS-based proteomics approaches and to develop MS target analysis, namely multiple reaction monitoring (MRM) analysis. This has contributed to achieve the ultimate goal that consists of the identification of the NO~2~-FA-protein adducts in complex biological samples as cells, tissues, biological fluids, which requires specific and targeted approaches. Bottom-up proteomics approaches are usually performed. Through these analytical approaches, it is possible to unequivocally identify the modified peptides after enzymatic digestion of NO~2~-FA-protein adduct, usually using trypsin, followed by the analysis of the tryptic peptides by reverse-phase (RP)-LC-MS and MS/MS. The addition of the NO~2~-FA moiety increases the retention time of the modified peptides [@bib42], which are identified on the mass spectra as singly, \[M+H\]^+^ ions, or multiple charged ions, \[M+nH\]^n+^, based on the mass shift against the unmodified peptide. This gives information on the nature of NO~2~-FA covalently attached to the protein. The observed mass shift in the mass spectra for the Michael adducts will be equal to the molecular weight of the NO~2~-FA. Thus, a mass shift of + 327 Da and + 325 Da corresponds to the addition of NO~2~-OA and NO~2~-LA, respectively [@bib42]. MS/MS data allows to confirm the nature of the modification and provides information on the fragmentation pattern of NO~2~-FA-peptide adducts. These data further allows to pinpoint the location of the modification site and thus the targeted residue in the peptide backbone [@bib103], [@bib104]. Detailed information to identify the sites of adduction is revealed by a mass shift of the typical *b* and *y* product ions of the adducted peptide, when compared with the non-modified one. The modified immonium ions are also useful to confirm the presence of a modified amino acid residue within the adducted peptide.

RP-LC-ESI-MS and MS/MS were used to detect lipoxidation adducts formed between NO~2~-OA or NO~2~-LA and GAPDH and GSH in vivo in healthy human red cells [@bib42]. This methodology was also applied to confirm the post-translational modifications of matrix metalloproteinase by NO~2~-OA [@bib75], and for the identification of reversible Michael adducts of NO~2~-OA and thiols of proteins and GSH in liver and plasma of NO~2~-OA-treated mice [@bib59]. Significant levels of protein cysteine adducts of NO~2~-OA were also observed in fresh olives, especially in the peel [@bib56]. AT~1~-R adducts with NO~2~-OA were quantified by HPLC-MS/MS using MRM scan mode in the negative-ion mode as BME adducts (BME-NO~2~-OA adducts) after a nucleophilic exchange of NO~2~-OA from AT~1~-R to BME. The presence of exchangeable NO~2~-OA demonstrated the direct adduction of AT~1~-R by NO~2~-OA, and therefore that AT~1~-R is a relevant cellular target for NO~2~-OA alkylation [@bib28]. RP-LC-MRM scan in the positive-ion mode (\[M+H\]^+^ ions) was applied for the characterization of NO~2~-LA-GSH adducts in vitro and further identification in MCF7 cells treated with NO~2~-LA [@bib76]. Nitroalkylation of albumin by NO~2~-OA and NO~2~-LA have been found in the plasma of mice gavage with these fatty acids [@bib62]. Nitroalkylation of p65 subunit of nuclear factor κB (NF-κB) was observed in vivo in myocardial tissue of a murine model of ischemia-reperfusion with intravenous supplementation of OA and LA [@bib1]. One study also reported the direct analysis by MALDI-TOF-TOF MS and MS/MS, in positive-ion mode, of adenine nucleotide translocase 1 (ATN 1) adducts after NO~2~-LA infusion into intact perfused heats allowing to pinpoint that the nitroalkylation of ANT1 by NO~2~-LA occurred on Cys57 [@bib34]. Adduction of NO~2~-OA to PPAR-γ [@bib47], and to Keap1 [@bib46] are also examples of biological detection and characterization of NO~2~-OA-protein adducts by MS.

The Michael addition reactions between NO~2~-FA and proteins is remarkably selective and depends on the nature and structural features of the NO~2~-FA. The fatty acyl chain length and the position of the electrophilic carbon, i.e., the position of the nitroalkene group, has a pivotal effect on the reactivity of NO~2~-FA [@bib102]. Therefore both factors regulate the formation of NO~2~-FA-protein adducts and the biological activity of the NO~2~-FA [@bib22], [@bib42], [@bib65], [@bib73], [@bib100], [@bib101]. In spite of its four possible isomers (at C9, C10, C12 or C13), only the NO~2~-LA isomers bearing the NO~2~ at C10 and C12 were reported to selectively bind to cysteine 285 (Cys285) in the ligand-binding domain and activate PPARγ [@bib101]. The C10 isomer of NO~2~-OA is more reactive toward to Cys285 in the ligand binding domain of PPARγ than the C9 isomer [@bib47]. On the other hand, Keap1 is easily activated by the C9 isomer via nitroalkylation of Cys273 and Cys288 [@bib22], [@bib46]. Xanthine oxidoreductase activity is preferentially inhibited by the C9 isomer of NO~2~-OA or a mixture of both C9 and C10 isomers [@bib73]. It has been reported that NO~2~-FA with shorter acyl chains interact stronger with Nrf2 and NF-kB [@bib60].

Overall, the identification of NO~2~-FA-protein adducts is important, because it may give information, as shown in several examples reported earlier, on the potential protein targets whose modulation by NO~2~-FA can have potential therapeutic interest.

4. Esterified nitro-fatty acids {#s0040}
===============================

4.1. Nitrated phospholipids and their lipoxidation adducts {#s0045}
----------------------------------------------------------

In spite of their free forms, NO~2~-FA can be stabilized by esterification in more complex lipids in hydrophobic compartments, as the biological membranes. Nitrated derivatives of phospholipids were identified in biomimetic model systems and also in vivo [@bib39], [@bib40]. In mimetic model studies, nitrated PLs were generated after in vitro incubation of PL standards (phosphatidylcholines, PCs and phosphatidylethanolamines, PEs) and NO~2~BF~4~, and its characterization was performed using C5-LC-MS and MS/MS in a Linear ion trap [@bib39], [@bib40]. Nitrated PCs and nitrated PEs were detected by HILIC-LC-MS and MS/MS-based lipidomic approaches in cardiac mitochondria from diabetic rats [@bib39] and cardiomyoblasts subjected to starvation [@bib40]. Nitrated 1-palmitoyl-2-oleyl-*sn*-glycero-3-phosphocholine (nitrated POPC) was reported to have antioxidant properties as scavenging agent, mediated by its anti-radical potential and ability to inhibit lipid peroxidation. Anti-inflammatory properties of nitrated POPC, related with its ability to inhibit iNOS expression in LPS-activated macrophages, were also reported [@bib105].

NO~2~-FA incorporation in PLs was also reported by using C18-HPLC-ESI-MS and MS/MS in API 4000 Q-trap triple quadrupole in adipocytes supplemented with NO~2~-SA, NO~2~-OA, NO~2~-cLA, and NO~2~-LA, before and after acidic hydrolysis. The incorporation yield and profile was specific for each supplemented NO~2~-FA and PL class, being PC the PL class with highest levels of incorporation of NO~2~-FA [@bib106].

Nitrated POPC was also found to have the capability to form adducts with peptides. The identification of the covalent adducts of NO~2~POPC with GSH was characterized by tandem MS in different instruments and the typical fragmentation pathways were disclosed for the first time. In this study, the NO~2~POPC-GSH adducts were generated under biomimetic conditions and characterized by direct infusion MS and MS/MS using different instrumental platforms including LXQ linear ion trap, Q-TOF 2, and Q-Exactive Hybrid Orbitrap. The observed fragmentation pattern of NO~2~POPC-GSH adducts included product ions that confirmed the presence of the phosphatidylcholine moiety (*m/z* 184.074 and neutral loss of 183 Da), the nitro group (neutral loss of HNO~2~), and ^\*^y~2~, ^\*^b~2~ and ^\*^C~1~ fragment ions of the modified peptide. All of these product ions pinpointing that NO~2~POPC was linked to a cysteine residue of GSH ([Fig. 6](#f0030){ref-type="fig"}) and can be used as reporter ions applied in the search of these lipoxidation adducts in biological samples [@bib49].Fig. 6ESI-MS spectra of mono charged \[M+H\]^+^ (A) and double charged \[M+ 2H\]^2+^ ions (B) of NO~2~POPC-GSH adducts, acquired in Q-Exactive Orbitrap, with identification of major fragmentation pathways. (Reprinted with permission from [@bib49], copyright 2018 \[John Wiley & Sons\]).Fig. 6

4.2. Nitrated triacylglycerides {#s0050}
-------------------------------

Nitrated triacylglycerides (NO~2~-FA-TAG) have been reported in rat plasma after oral administration of NO~2~-OA, together with β-oxidation and dehydrogenation derivatives of NO~2~-FA-TAG in adipocytes supplemented with NO~2~-OA. These studies were performed by C18-HPLC-ESI-MS and MS/MS in API4000 Q-trap triple quadrupole and LTQ Velos Orbitrap instruments [@bib41]. Another study reported the differential esterification profile of NO~2~-FA and their metabolites in TAGs in adipose tissue of rats fed with 10-NO~2~-OA. By using C18-HPLC-ESI-MS and MS/MS in API 4000 Q-trap triple quadrupole, the NO~2~-FA were observed to be preferentially incorporated in monoacyl- and diacylglycerides. This was found to be in opposite to its reduced metabolites, which were favorably incorporated in TAGs. These observations were corroborated by the analysis of the lipid polar and neutral fractions from adipocytes supplemented with NO~2~-SA (nitro-stearic acid), NO~2~-OA, NO~2~-cLA, and NO~2~-LA, after acidic hydrolysis [@bib106].

The occurrence of nitrated phospholipids and triacylglycerides can be of high relevance at biological level. The NO~2~-FA-containing phospholipids and triacylglycerides can act as a reservoir of NO~2~-FA. Additionally, these esterified NO~2~-FA can be further mobilized by lipases in turn to exert their adaptive and anti-inflammatory signaling actions. In the case of NO~2~-FA-containing phospholipids, the NO~2~-FA moiety seems to be able to retain the electrophilic character, and thus the ability to undergo reversible reactions via Michael addition with key proteins. Also, these phospholipid-esterified NO~2~-FA can have an impact as anti-inflammatory and cytoprotective species. The nitration of esterified NO~2~-FA or its incorporation into more complex lipids, together with the occurrence of lipoxidation products of NO~2~-FA-containing phospholipids, and perhaps NO~2~-FA-TAGs, can also contribute to the systemic distribution and metabolism of NO~2~-FA.

5. Conclusion and future perspectives {#s0055}
=====================================

NO~2~-FA own important physiological functions that are mediated via formation of lipoxidation adducts and associated regulation of protein function. Several signaling proteins, with key roles in anti-inflammatory, anti-hypertensive, anti-hyperglycemic, and cytoprotective pathways, are targets of NO~2~-FA adduction. This points to potential for new therapeutic strategies in important non-communicable diseases as cardiovascular, renal, pulmonary, and metabolic diseases. Mass spectrometry is a promising analytical tool in the detection of NO~2~-FA-protein adducts. Nevertheless, there is a need for new methodological developments to improve the detection of these elusive lipoxidation adducts, and to obtain more insights regarding the protein targets of NO~2~-FA and its roles in biological signaling pathways.
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